权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting pyrimidine biosynthesis in pancreatic ductal adenocarcinoma

胰腺导管腺癌中靶向嘧啶生物合成

基本信息

批准号：
10672389
负责人：
Nicholas James Mullen
金额：
$ 5.27万
依托单位：
UNIVERSITY OF NEBRASKA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-07-12 至 2025-07-11
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10672389
关键词：
Abraxane Address Affect Agammaglobulinaemia tyrosine kinase American Anabolism Animal Model Antineoplastic Agents Automobile Driving Biochemical Biological Assay Cancer Etiology Cell Line Cell Proliferation Cell Survival Cells Cessation of life Clinical Clinical Trials Clinical effectiveness Combined Modality Therapy Deoxyribonucleosides Dependence Dihydroorotate Dehydrogenase Inhibitor Dihydroorotate dehydrogenase Disease Down-Regulation Drug Combinations Drug Compounding Drug Targeting Drug usage Effectiveness Enzymes FDA approved Follow-Up Studies Genes Genetic Genetic Transcription Glucose Goals Harvest Human Hyperactivity Immune response Immune system Immunocompetent Immunocompromised Host Implant In Vitro Isotope Labeling Label Malignant Neoplasms Malignant neoplasm of pancreas Mediating Metabolic Metabolic Pathway Metabolism Monitor Mus Nucleosides Nucleotide Biosynthesis Nucleotides Nutrient Oncogenic Pancreatic Ductal Adenocarcinoma Pathway interactions Patients Pattern Pharmaceutical Preparations Pharmacotherapy Phosphorylation Phosphotransferases Population Process Proliferating Proteins Pyrimidine Pyrimidine Nucleosides Pyrimidine Nucleotides Quality of life Resistance Ribose Signal Pathway Signal Transduction Site Solid Survival Rate System Toxic effect Treatment Efficacy Tumor Tissue Tumor-infiltrating immune cells Tyrosine Kinase Inhibitor Validation anticancer treatment base cancer cell cancer type chemotherapy combat combinatorial deprivation design effective therapy efficacy evaluation efficacy testing enzyme pathway experimental group experimental study genotoxicity implantation improved in vivo in vivo evaluation inhibitor inorganic phosphate kinase inhibitor metabolic phenotype metabolomics mouse model novel nucleotide metabolism pancreatic ductal adenocarcinoma cell pre-clinical resistance mechanism response single-cell RNA sequencing small molecule standard of care targeted treatment transcriptome sequencing transcriptomics treatment strategy tumor tumor growth tumor microenvironment tumor progression uptake

项目摘要

Project Summary Pancreatic ductal adenocarcinoma (PDAC) is almost universally lethal and is projected to become the second-leading cause of cancer related deaths in the US by 2030. Conventional (genotoxic) chemotherapy approaches that make up the current standard of care are mostly ineffective and prolong survival of advanced PDAC patients by less than one year on average. Similarly, small molecule drugs targeting aberrantly activated oncogenic signaling pathways have shown disappointing clinical results and accordingly have failed to gain FDA approval for PDAC. An alternative strategy to these two approaches is to exploit metabolic dependencies that are unique to malignant cells by virtue of their deranged cellular metabolism. While there are well-characterized resistance mechanisms to genotoxic and targeted therapies, deprivation of certain nutrients critical for proliferation of malignant cells appears to be an insurmountable barrier for cancer progression. However, cells have redundant means of acquiring these critical nutrients, and so inhibition of a single metabolic enzyme is generally not sufficient to deny them to cancer cells. Thus, combinatorial blockade of multiple metabolic pathways could be required to impose deficiency of key metabolites on malignant cells. Pyrimidine nucleotides represent a class of metabolites that has been shown in numerous studies to be essential for PDAC and a host of other malignancies. Importantly, there are several clinical grade inhibitors of pyrimidine synthesis enzymes that have shown preclinical promise as anticancer agents. However, these drugs have uniformly failed to show efficacy in clinical trials in which they were used as monotherapy against various malignancies. One potential explanation for this is that there are two major pathways by which cells generate nucleotides, termed the de novo and salvage pathways, and these inhibitors block the key de novo pathway enzyme dihydroorotate dehydrogenase (DHODH), thus leaving the salvage pathway fully intact. We’ve characterized the response of various PDAC cell lines to the DHODH inhibitor brequinar (BQ). We found that some PDAC cell lines are highly resistant to BQ in cell viability assays compared to their more sensitive counterparts. We then screened some 350 known kinase inhibitor compounds to probe for any that could restore BQ sensitivity in our resistant PDAC cell lines, and this nominated the preclinical BTK inhibitor CNX-774 as the strongest hit. Follow-up studies have shown that combined BQ/CNX-774 treatment leads to profound cell viability loss and pyrimidine depletion, compared to either drug alone, in BQ-resistant PDAC cells. Furthermore, we have strong evidence that CNX-774 is acting in an off-target manner to inhibit pyrimidine salvage. Thus, the goal of this study is to uncover the mechanism by which CNX-774 is sensitizing PDAC cells to BQ and determine if this drug combination is efficacious in our preclinical PDAC mouse models. Our goal is to provide preclinical support for this metabolic combination therapy as a potential PDAC treatment.

项目总结